Piper Jaffray Starts Nektar Therapeutics (NKTR) Coverage with $125.0000 Target; Sirva (SIR)’s Sentiment Is 1.33

April 13, 2018 - By rebbecca

Nektar Therapeutics (NASDAQ:NKTR) Logo

Sirva Inc (SIR) investors sentiment increased to 1.33 in 2017 Q4. It’s up 0.30, from 1.03 in 2017Q3. The ratio is better, as 88 investment professionals increased or opened new holdings, while 66 sold and decreased equity positions in Sirva Inc. The investment professionals in our database now possess: 42.18 million shares, up from 41.58 million shares in 2017Q3. Also, the number of investment professionals holding Sirva Inc in top ten holdings decreased from 2 to 1 for a decrease of 1. Sold All: 14 Reduced: 52 Increased: 61 New Position: 27.

Professional analysts at Piper Jaffray issued “Buy” rating on Nektar Therapeutics (NASDAQ:NKTR). The firm has begun coverage in analysts report shared with investors on Friday morning. Piper Jaffray’s PT gives upside of 20.49% from the company’s current stock price.

Analysts await Select Income REIT (NASDAQ:SIR) to report earnings on April, 24. They expect $0.65 EPS, up 10.17% or $0.06 from last year’s $0.59 per share. SIR’s profit will be $58.16 million for 7.20 P/E if the $0.65 EPS becomes a reality. After $0.68 actual EPS reported by Select Income REIT for the previous quarter, Wall Street now forecasts -4.41% negative EPS growth.

Select Income REIT is a publicly owned equity real estate investment trust externally managed by The RMR Group LLC. The company has market cap of $1.68 billion. The firm invests in the real estate markets in Hawaii. It has a 24.99 P/E ratio. It primarily owns office and industrial buildings under long-term leases to single tenants.

Ratings analysis reveals 100% of Select Income REIT’s analysts are positive. Out of 2 Wall Street analysts rating Select Income REIT, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. SIR was included in 2 notes of analysts from August 22, 2016. The firm earned “Mkt Outperform” rating on Monday, August 22 by JMP Securities. The rating was initiated by FBR Capital with “Outperform” on Monday, August 22.

Boulegeris Investments Inc. holds 2.2% of its portfolio in Select Income REIT for 168,065 shares. Independent Order Of Foresters owns 84,240 shares or 1.87% of their US portfolio. Moreover, V3 Capital Management L.P. has 1.48% invested in the company for 429,000 shares. The Texas-based Hillcrest Asset Management Llc has invested 1.41% in the stock. Benchmark Capital Advisors, a New York-based fund reported 70,650 shares.

The stock decreased 2.35% or $0.45 during the last trading session, reaching $18.72. About 429,890 shares traded or 2.56% up from the average. Select Income REIT (SIR) has declined 25.14% since April 13, 2017 and is downtrending. It has underperformed by 36.69% the S&P500.

Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It is negative, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Zacks Invest Management holds 11,821 shares or 0.02% of its portfolio. 22.36 million were reported by Primecap Management Company Ca. Susquehanna Group Llp reported 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Rhumbline Advisers, a Massachusetts-based fund reported 369,568 shares. Profund Ltd Limited Liability Company reported 80,937 shares stake. Fincl Bank Of Mellon Corp has 1.97 million shares. Putnam Invests Ltd reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Fmr Ltd Liability Co invested in 0.08% or 11.24 million shares. Eqis Capital Mgmt has invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Stifel Corporation reported 0% in Nektar Therapeutics (NASDAQ:NKTR). Aqr Mgmt Ltd Limited Liability Company invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Manufacturers Life Insur The reported 112,452 shares. Paradigm Asset Limited Company accumulated 450 shares or 0.01% of the stock. Pointstate Limited Partnership stated it has 3.93 million shares. Schwab Charles Invest Management Inc has invested 0.04% in Nektar Therapeutics (NASDAQ:NKTR).

The stock increased 0.94% or $0.97 during the last trading session, reaching $103.74. About 986,032 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 13, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 EPS, down 2.38% or $0.01 from last year’s $-0.42 per share. After $-0.14 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14% negative EPS growth.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $67’s average target is -35.42% below currents $103.74 stock price. Nektar Therapeutics had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, November 8. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Tuesday, May 30 by Roth Capital. Aegis Capital initiated the stock with “Buy” rating in Tuesday, November 8 report. The firm earned “Buy” rating on Wednesday, October 18 by Jefferies. Mizuho maintained the shares of NKTR in report on Thursday, March 29 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Friday, April 6. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) on Thursday, January 7 with “Overweight” rating. On Monday, April 2 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Tuesday, July 18 by J.P. Morgan. Roth Capital maintained the stock with “Buy” rating in Thursday, July 20 report.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $16.69 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Select Income REIT (NASDAQ:SIR) Institutional Positions Chart